瑞银发表报告，列出最具潜力超市场预期收益((Buy rated HK listed stocks with highest UBSe earnings upside above consensus estimate)的港股买入名单：股份│瑞银与同业对企业今明两年综合盈测差异康希诺生物(06185.HK) +3.320 (+7.488%) 沽空 $7.66百万; 比率 4.437% │97%石药集团(01093.HK) +0.340 (+3.520%) 沽空 $4.56亿; 比率 23.064% │60%三生制药(01530.HK) +1.820 (+5.971%) 沽空 $2.79亿; 比率 20.925% │42%科济药业-B(02171.HK) +1.200 (+5.865%) 沽空 $1.48千万; 比率 23.282% │42%上石化(00338.HK) +0.010 (+0.746%) 沽空 $96.99万; 比率 12.927% │37%越秀地产(00123.HK) +0.050 (+1.096%) 沽空 $8.94百万; 比率 21.976% │35%金风科技(02208.HK) +0.230 (+3.186%) 沽空 $2.25百万; 比率 3.919% │33%科伦博泰生物-B(06990.HK) +28.800 (+7.125%) 沽空 $4.07千万; 比率 7.460% │27%中信建投证券(06066.HK) +0.360 (+2.878%) 沽空 $2.23千万; 比率 16.248% │26%恒瑞医药(01276.HK) +2.000 (+2.532%) │25%海丰国际(01308.HK) +0.380 (+1.487%) 沽空 $1.88千万; 比率 36.644% │23%药明康德(02359.HK) +3.000 (+2.991%) 沽空 $2.08亿; 比率 21.514% │22%(wl/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-08-05 16:25。)